A Lilly spokesman said the company will invest multi-millions in its biotechnolgy programs in order to develop new multi-specific therapies for a variety of diseases. Multi-specific therapies use molecular biology techniques to combine more than one drug "mechanism of action" on a single drug molecule. This differs from combination therapies which involve more than one drug.
Lilly plans to hire more biochemists and biologists to support this research effort. Therapeutic areas to be pursued include diabetes, cancer, and autoimmune diseases where often one drug is not sufficient to effectively treat the disease. See Bloomberg.
Posted by Bruce Lehr July 5th 2011.
Comments